Laryngorhinootologie 2024; 103(S 02): S212
DOI: 10.1055/s-0044-1784689
Abstracts │ DGHNOKHC
Head-Neck-Oncology: Tumor marker

The lymphocyte-thrombocyte-CRP (LTC) score as a pre-therapeutic prognostic marker in patients with head and neck cancer (HNC)

Michael Peis
1   Universitätsklinikum Essen, Hals-, Nasen-, Ohrenheilkunde, Essen
,
Vinithagowry Sivakumar
1   Universitätsklinikum Essen, Hals-, Nasen-, Ohrenheilkunde, Essen
,
Lukas Boosfeld
1   Universitätsklinikum Essen, Hals-, Nasen-, Ohrenheilkunde, Essen
,
Sebastian Waßenberg
2   05. Statistik, Düsseldorf
,
Stefan Mattheis
1   Universitätsklinikum Essen, Hals-, Nasen-, Ohrenheilkunde, Essen
,
Jadwiga Jablonska
1   Universitätsklinikum Essen, Hals-, Nasen-, Ohrenheilkunde, Essen
,
Stephan Lang
1   Universitätsklinikum Essen, Hals-, Nasen-, Ohrenheilkunde, Essen
,
Timon Hussain
3   Ludwig-Maximilians-Universität München, Klinik für Hals-, Nasen-, Ohrenheilkunde, München
,
Cornelius Kürten
1   Universitätsklinikum Essen, Hals-, Nasen-, Ohrenheilkunde, Essen
› Author Affiliations
› Further Information
Also available at
 

Introduction Systemic inflammation, measured for example as neutrophil-lymphocyte ratio (NLR) or systemic inflammatory index (SII), is associated with a negative influence on survival in patients with HNC. These indices require laboratory analyses and mathematical calculations. This study examines a simple three-point scoring system based on lymphocyte-, thrombocyte- and CRP levels has prognostic significance.

Methods The pre-therapeutic laboratory data of 994 patients was collected by retrospective chart review. Patients with elevated levels of lymphocytes, thrombocytes or CRP received one point for each pathologically elevated laboratory result (range 0 – 3). Using SPSS (version 29 for MAC), we analysed and visualized overall and relapsing-free survival using Kaplan-Meier curves and the log rank test.

Results 375 (43.0%) patients had a score of 0, 310 (35.5%) patients had a score of 1, 142 (16.3%) patients had a score of 2, and 45 (5.2%) patients had a score of 3. The Kaplan Meier analysis showed a significantly longer overall survival with an LCT score of 0 compared to patients with an increased values (median survival 100 months for a score of 0, 53 months for a score of 1, 25 months for a score of 2 and 12 months for score of 3). A similar relationship can be demonstrated for relapse-free survival (median survival 110 months for a score of 0, 77 months for a score of 1, 70 months for a score of 2 and 33 months for a score of 3).

Conclusion The LTC score can be used as a pre-therapeutic prognostic marker with regard to overall survival, as well as relapse-free survival, in patients with HNC. In the future, a multivariate comparison will be performed, which includes other prognostic markers, such as tumour stage and p16 status, as well as the NLR and the SSI.



Publication History

Article published online:
19 April 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany